Life Technologies, TrimGen Collaborate on Cancer Mutation Assays | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies today announced that it will sell cancer mutation assays supplied by TrimGen to the research market.

Under the collaboration, assays for detecting KRAS and BRAF mutations will be developed and manufactured by TrimGen, which will supply the assays to Life Technologies. The assays will be sold under the Applied Biosystems brand and run on AB's capillary electrophoresis sequencing systems, including its new 3500 Series Genetic Analyzer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.